康寧醫院(02120.HK):根據H股獎勵信託計劃第三次授出33.5萬股獎勵股份
格隆匯6月18日丨康寧醫院(02120.HK)發佈公吿,2024年6月18日,根據H股獎勵信託計劃,董事會決議向52名選定參與者(“第三次授予選定參與者”)授出33.5萬股獎勵股份(“第三次授予”),佔公吿日期已發行股本約0.45%,授予價格為人民幣7元╱股。
第三次授予選定參與者包括公司中層管理人員、技術骨幹。經計及聯交所於2024年6月17日(即本公吿日期前的最後交易日)發出的每日報價表所載每股H股收市價11.90港元,33.5萬股獎勵股份的價值為398.65萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.